Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS).

Roy SK, Kendrick D, Sadowitz BD, Gatto L, Snyder K, Satalin JM, Golub LM, Nieman G.

Pharmacol Res. 2011 Dec;64(6):580-9. doi: 10.1016/j.phrs.2011.06.012. Epub 2011 Jun 21. Review.

2.

Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model.

Steinberg J, Halter J, Schiller H, Gatto L, Carney D, Lee HM, Golub L, Nieman G.

Shock. 2005 Oct;24(4):348-56.

PMID:
16205320
3.

Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis + ischemia/reperfusion-induced lung injury.

Roy SK, Kubiak BD, Albert SP, Vieau CJ, Gatto L, Golub L, Lee HM, Sookhu S, Vodovotz Y, Nieman GF.

Shock. 2012 Apr;37(4):424-32. doi: 10.1097/SHK.0b013e318245f2f9.

PMID:
22258231
4.

A tetracycline analog improves acute respiratory distress syndrome survival in an ovine model.

Zhou X, Wang D, Ballard-Croft CK, Simon SR, Lee HM, Zwischenberger JB.

Ann Thorac Surg. 2010 Aug;90(2):419-26. doi: 10.1016/j.athoracsur.2010.04.052.

PMID:
20667323
5.

Metalloproteinase inhibition prevents acute respiratory distress syndrome.

Carney DE, McCann UG, Schiller HJ, Gatto LA, Steinberg J, Picone AL, Nieman GF.

J Surg Res. 2001 Aug;99(2):245-52.

PMID:
11469893
6.

Matrix metalloproteinase inhibitor: differential effects on pulmonary neutrophil and monocyte sequestration following cardiopulmonary bypass.

McCann UG 2nd, Gatto LA, Searles B, Carney DE, Lutz CJ, Picone AL, Schiller HJ, Nieman GF.

J Extra Corpor Technol. 1999 Jun;31(2):67-75.

PMID:
10724645
7.

Protein C and acute inflammation: a clinical and biological perspective.

Christiaans SC, Wagener BM, Esmon CT, Pittet JF.

Am J Physiol Lung Cell Mol Physiol. 2013 Oct 1;305(7):L455-66. doi: 10.1152/ajplung.00093.2013. Epub 2013 Aug 2. Review.

8.

Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases.

Castro MM, Kandasamy AD, Youssef N, Schulz R.

Pharmacol Res. 2011 Dec;64(6):551-60. doi: 10.1016/j.phrs.2011.05.005. Epub 2011 May 31. Review.

PMID:
21689755
9.

Infections and the inflammatory response in acute respiratory distress syndrome.

Headley AS, Tolley E, Meduri GU.

Chest. 1997 May;111(5):1306-21.

PMID:
9149588
10.

Aspirin as a potential treatment in sepsis or acute respiratory distress syndrome.

Toner P, McAuley DF, Shyamsundar M.

Crit Care. 2015 Oct 23;19:374. doi: 10.1186/s13054-015-1091-6. Review.

11.

A role for the anti-inflammatory properties of tetracyclines in the prevention of acute lung injury.

Nieman GF, Zerler BR.

Curr Med Chem. 2001 Feb;8(3):317-25. Review.

PMID:
11172686
12.

Evolution of treatments for patients with acute lung injury.

Esper AM, Martin GS.

Expert Opin Investig Drugs. 2005 May;14(5):633-45. Review.

PMID:
15926869
14.

Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.

Gu Y, Lee HM, Sorsa T, Salminen A, Ryan ME, Slepian MJ, Golub LM.

Pharmacol Res. 2011 Dec;64(6):573-9. doi: 10.1016/j.phrs.2011.06.023. Epub 2011 Jul 13. Review.

PMID:
21771657
15.

Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis.

Sharifov OF, Xu X, Gaggar A, Grizzle WE, Mishra VK, Honavar J, Litovsky SH, Palgunachari MN, White CR, Anantharamaiah GM, Gupta H.

PLoS One. 2013 May 14;8(5):e64486. doi: 10.1371/journal.pone.0064486. Print 2013.

16.

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup..

Intensive Care Med. 2013 Feb;39(2):165-228. doi: 10.1007/s00134-012-2769-8. Epub 2013 Jan 30.

PMID:
23361625
17.

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.

Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup..

Crit Care Med. 2013 Feb;41(2):580-637. doi: 10.1097/CCM.0b013e31827e83af.

PMID:
23353941
18.

[Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome].

Lyu G, Wang X, Jiang W, Cai T, Zhang Y.

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014 May;26(5):325-9. doi: 10.3760/cma.j.issn.2095-4352.2014.05.008. Chinese.

19.

Acute respiratory distress syndrome: pharmacological treatment options in development.

Hite RD, Morris PE.

Drugs. 2001;61(7):897-907. Review.

PMID:
11434447
20.

Definitions and pathophysiology of sepsis.

Sagy M, Al-Qaqaa Y, Kim P.

Curr Probl Pediatr Adolesc Health Care. 2013 Nov-Dec;43(10):260-3. doi: 10.1016/j.cppeds.2013.10.001. Review.

PMID:
24295606

Supplemental Content

Support Center